NDAORALTABLET
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PEXEVA (paroxetine mesylate) by Bel Air Pharmaceuticals. Approved for hot flashes, postmenopausal symptoms. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEXEVA (paroxetine mesylate) is an oral selective serotonin reuptake inhibitor (SSRI) approved for hot flashes and postmenopausal symptoms. It works by inhibiting neuronal reuptake of serotonin in the central nervous system, potentiating serotonergic activity.
$0.508MPart D
LOE ApproachingProduct is in late lifecycle with minimal Part D spending ($508K in 2023), indicating limited market presence and likely declining team headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (2)
Worked on PEXEVA at Bel Air Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.